• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OncoSec announces positive results in metastatic melanoma case study

December 4, 2020 By Brian Buntz

OncosecThe International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma.

The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression in the skin, brain, liver and lymph nodes.

The patient also had rheumatoid arthritis.

Physicians treated the patient’s subcutaneous and in-transit lesions with TAVO and intravenous pembrolizumab. TAVO is directly injected into the tumor using electroporation. All of the lesions treated with the method resolved. The patient’s brain and lung tumors also regressed, and lymph node disease in the chest and lungs was also resolved while brain metastasis was stable.

The study authors concluded that the therapy led to a whole-body response. They also determined that the combination of pembrolizumab and tavokinogene telseplasmid is a promising therapy for metastatic melanoma that resists treatment with immune checkpoint inhibitors.

The patient received the therapy as part of OncoSec’s expanded access program. “This is yet another example of the cruciality of robust expanded access programs, as they provide hope to patients who often do not meet the stringent inclusion clinical trial requirements,” said Dr. James Nitzkorski of Vassar Brothers Medical Center in prepared remarks.

 

Filed Under: Immunotherapy, Oncology, Surgical Tagged With: electroporation, Keytruda, melanoma, Oncosec, pembrolizumab, TAVO, tavokinogene telseplasmid

IN CASE YOU MISSED IT

  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering
  • BD stock up on Street-beating preliminary quarterly revenue numbers

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS